HighGravityDataNeurocrine Biosciences — Jul 30, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000914475-26-000035
Showing in the filing
INGREZZA® (valbenazine) 2026 Net Sales
“$2.825 to $2.875 Billion”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 16
INGREZZA® (valbenazine) 2026 Net Sales for FY2026
“$2.825 to $2.875 Billion”
IPR&D for FY2026
“$23”
INGREZZA Net Product Sales
“$2,700 - $2,800”
INGREZZA Net Product Sales for FY2026
“$2,825 - $2,875”
GAAP R&D
“$1,200 - $1,250”
GAAP R&D for FY2026
“$1,275 - $1,325”
Non-GAAP R&D
“$1,110 - $1,160”
Non-GAAP R&D for FY2026
“$1,140 - $1,190”
IPR&D
“$20”
GAAP SG&A
“$1,375 - $1,400”
GAAP SG&A for FY2026
“$1,575 - $1,600”
Non-GAAP SG&A
“$1,240 - $1,265”
Non-GAAP SG&A for FY2026
“$1,325 - $1,350”
GAAP Amortization of Acquired Intangible Ass…
“Not applicable”
GAAP Amortization of Acquired Intangible Ass… for FY2026
“$85 - $90”
R&D development milestones expense for FY2026
“approximately $25 million”
Exhibit 99.1 · the passage around this item
Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO , July 30, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026. “Our second quarter performance demonstrates the power of a strategy designed to compound over time,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “As our commercial portfolio of first-in-class medicines continues to grow, so does our capacity to reinvest in innovation, advance a differentiated late-stage pipeline and pursue strategic opportunities that strengthen the company for the long term. With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we are building an enduring company poised to deliver meaningful value for patients and shareholders for years to come.” Total Revenue Highlights Three Months Ended June 30, (unaudited, in millions, except per share data) 2026 2025 YoY Growth Revenues: INGREZZA Net Product Sales $ 716 $ 624 15% CRENESSITY ® (crinecerfont) Net Product Sales 184 53 247% VYKAT ® (diazoxide choline) XR Net Produc
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.